mHSPC VL

Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell

Details
Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell's study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 343,000 patients globally, examines the application of doublets and triplets in treatm...

Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt

Details
Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...

Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein

Details
Zach Klaassen converses with Daniel Saltzstein about the collaborative approach to treating metastatic hormone-sensitive prostate cancer with triplet therapy or maximum androgen blockade. Dr. Saltzstein describes their unique practice set up in San Antonio, where a medical oncologist is part of their urology team. This shared patient focus facilitates seamless collaboration and treatment managemen...

Building an Integrated, Multidisciplinary Team to Optimize Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Chandler Park & Ryan Malone

Details
Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases. They discuss patient selection for tripl...

Communication for Optimal Care in Patients Selected for Triplet Therapy Between Urology and Community Oncology - Vahan Kassabian & Sreekanth Reddy

Details
Zach Klaassen engages with Vahan Kassabian and Sreekanth to discuss the continuum of care for patients with metastatic hormone-sensitive prostate cancer, particularly in the context of triplet therapy based on the ARASENS data. The conversation reveals their longstanding professional relationship, developed through mutual patients and a shared interest in urological oncology. They discuss the logi...

Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy

Details
Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...

Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyon...

Details
Whether disease burden in patients with metastatic castration-sensitive prostate cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide treatment effect in TITAN patients with mCSPC by disease volume, metastasis number and timing of metastasis presentation. Biographies: Axel S. Merseburger, MD, PhD, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany Rela...

Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu

Details
Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...

ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG

Details
Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...

Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic

Details
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...